Scores by kind of claim
Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.
-
Factual claims
Statements about the present or the past, checked against the record: did they hold up?
68 61 75 -
Predictions
Statements about events outside the person's control, checked once they fell due: did they come true?
42 25 60 -
Promises
Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?
Insufficient record: 0 promises resolved, 5 needed for a score.
All types combined: 65 (likely 58 to 71, high confidence), from 78 claims: 69 factual claims, 9 predictions. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.
Ray Kurzweil's claims
24 claims
“Very often, the first several solutions tested on humans are not ideal and lead to other solutions that also take a few years to develop and test.”
Ray Kurzweil, columnist May 2020 AI-powered bio-tech can help deploy a vaccine in record time (Kurzweil Library / Wired)
Very often the first several solutions tested on humans are not ideal and lead to other solutions that also take a few years to develop and test.
Mostly true True in substance, wrong in a detail.
The second judge said mixed; the verdict shown is the first judge's.
Said for an organisation they lead or work for; it counts on both records.
What would count as true or false
Judge as of 2020. True: evidence shows that early candidates tested in humans very often fail or prove suboptimal, leading to follow-on candidates that take years to develop (e.g., high clinical attrition rates, with roughly 90% of candidates failing). Mostly true: the general pattern holds, but 'a few years' for follow-ons is somewhat imprecise. Mixed: attrition is high, but evidence that failures typically lead to multi-year follow-on development is weak. Mostly false: the pattern applies only in narrow areas and is stated as general. False: most first candidates succeed, or follow-ons are quick.
Evidence
- Need for NAMs: A systematic evidence synthesis revealing over half a century of drug development failure PMC (NCBI) · 21 July 2026
“Success rates in drug development are notoriously low, with fewer than 1 out of 10 drug candidates that enter clinical trials gaining marketing approval (Dowden and Munro, 2019; Thomas et al., 2021).”
- Need for NAMs: A systematic evidence synthesis revealing over half a century of drug development failure PMC (NCBI) · 21 July 2026
“The earliest failure rate in our dataset describes the attrition of 211 compounds evaluated in clinical trials between 1963 and 1965, with a calculated failure rate of 90.5% (Sheck et al., 1984).”
- Estimation of clinical trial success rates and related parameters Biostatistics (Oxford Academic) · April 2019
“For example, oncology has a 3.4% success rate in our sample vs. 5.1% in prior studies.”
- Publication of Drug Failures in Late-Stage Clinical Development JAMA Internal Medicine · 1 December 2016
“Among 640 novel therapeutics, 344 (54%) failed in clinical development, 230 (36%) were approved by the US Food and Drug Administration (FDA), and 66 (10%) were approved in other countries but not by the FDA.”
Reasoning
Independent sources show high clinical attrition: E1 reports that fewer than 1 in 10 candidates entering clinical trials gain approval, E2 records a 90.5% failure rate as early as the 1960s, E3 gives a 3.4% oncology success rate, and E4 finds 54% of 640 novel therapeutics failed in clinical development. This matches the attrition pattern the criteria cite as support for the claim. None of the evidence directly documents that failures lead to follow-on candidates taking a few years, so that part is somewhat imprecise and the claim is rated mostly true rather than true.
Cite this claim
Ray Kurzweil, “Very often the first several solutions tested on humans are not ideal and lead to other solutions that also take a few years to develop and test.” (said May 2020). Verdict: mostly true. Reliability API, claim c_34521b7d8319, method 0.1.0+28da144b. https://epistacklabs.com/claims/c_34521b7d8319
Claims without a verdict
Is a verdict here wrong, or do you speak for Ray Kurzweil? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.